Atlas Private Wealth Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Atlas Private Wealth Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-233	Closed	-$20K	–	454
2021 Q3	$20K	Sell	233 -134	-37%	-$13.9K	0.01%	354
2021 Q2	$57K	Sell	367 -552	-60%	-$80.1K	0.03%	218
2021 Q1	$145K	Sell	919 -2,057	-69%	-$433K	0.08%	127
2020 Q4	$691K	Sell	2,976 -200	-6%	-$46.3K	0.46%	46
2020 Q3	$696K	Sell	3,176 -67	-2%	-$16.4K	0.58%	38
2020 Q2	$921K	Buy	+3,243	New	+$959K	0.82%	27

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Atlas Private Wealth Advisors's KPTI Position: Q4 2021 in Review

Atlas Private Wealth Advisors sold out of Karyopharm Therapeutics (KPTI) in Q4 2021, closing a stake of 233 shares — an estimated $20K sold.

Atlas Private Wealth Advisors first reported a position in KPTI in Q2 2020 and held it in 6 quarters. The position peaked at $921K in Q2 2020. 143 funds tracked by Wall St. Rank hold KPTI as of Q4 2021.

Atlas Private Wealth Advisors reported no remaining Karyopharm Therapeutics position as of Q4 2021 after selling out during the quarter.
Atlas Private Wealth Advisors sold 233 Karyopharm Therapeutics shares in Q4 2021, an estimated $20K.
Atlas Private Wealth Advisors first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 6 quarters.
Atlas Private Wealth Advisors's Karyopharm Therapeutics position peaked at $921K in Q2 2020.
143 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2021.

Based on Atlas Private Wealth Advisors's 13F filing for Q4 2021, filed 21 Apr 2022.